Sir John Bell

News

Failure to strike a Brexit deal allowing alignment with the European Medicines Agency would be ‘catastrophic’ for the UK life sciences sector.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.